Recurrent ovarian cancer chemotherapy new method - conventional chemotherapy drug efficacy forecast molecular targeted chemotherapy
Ovarian cancer screening, treatment and prevention of the Current Situation and Prospect Although ovarian cancer chemotherapy drug developed considerable progress has been made, but patients with ovarian cancer and the overall s...
CA-125 blood test results are forecast ovarian cancer the best indicators Ovarian cancer is prone than Caucasian Europe and the United States, but recently the Taiwan people with the risk of ovarian cancer is also...
Ovarian cancer is the worst prognosis of gynecologic tumors. Patients with advanced epithelial ovarian cancer five-year survival rates generally below 30%, mainly in patients with relapsing most (about 75%), relapse after chemotherapy to poor results.
For the treatment of recurrent ovarian cancer chemotherapy drugs many, no less than 10 species, but only clinical remission rate of 20% to 30%, no progress median survival time (PFS) for 2 to 6 months, the median overall survival (OS) for six to 12 months. Therefore, to improve the efficacy of chemotherapy drugs delay, but the development of new drugs is very difficult, efficient use of existing drugs is an effective way to <BR>.
How to achieve "efficient use"? Based on the characteristics of individual tumors targeted drugs to choose, "individual treatment" is a highly efficient use of the effective method. The current "individual treatment" mainly include: chemotherapy drug sensitivity test done before, and p53 gene therapy gefitinib molecular targeted therapy. The first method of the rate is not high, the latter two methods of the weak, normally only from conventional chemotherapy sensitizer role.
Based on the above considerations, we propose a new individualized treatment - chemotherapy drug efficacy forecast conventional molecular targeted therapy (PMTC), which is based on conventional chemotherapy drug molecules corresponding projections of expression, choice of chemotherapeutic drugs. Their theory is based on studies have found that each has its corresponding chemotherapy drug efficacy prediction elements, such as the p53 tumor was relatively resistant to cisplatin and paclitaxel on relatively sensitive; Pgp positive tumor relatively resistant to Taxol, and the relatively sensitive to gemcitabine,. Therefore, it can be based on different tumor expression of the individual elements of different projections, forecasts sensitive to the choice of chemotherapy drugs to avoid resistance forecast of chemotherapy drugs in order to achieve the best effect, this means we named PMTC. This method reliable test results by selecting powerful conventional chemotherapy drug, can avoid the low rate sensitivity test with the shortcomings can be avoided "gene therapy" and "molecular targeted therapy" in the weak shortcomings.
From June 2004, prospective clinical application PMTC using immunohistochemical methods of detection of p53 and six forecast molecule expression, according to the results of second-line or third-line choice of drug for the treatment of chemotherapy. Results included PMTC group of nine cases of epithelial ovarian cancer in patients with recurrent clinical remission rate was 78% (7 / 9), five cases of early recurrence in patients with full remission. Meanwhile, we also reviewed the hospital past recurrent epithelial ovarian cancer in patients with the medical records, hospital information I recently received 23 cases of second-tier and third-line treatment of patients with chemotherapy (traditional chemotherapy group) clinical remission rate was 26% (6 / 23 patients), chemotherapy group PMTC significant remission rate than traditional chemotherapy group, the difference was statistically significant (P = 0.011).
Therefore, we believe that the exploration of the clinical trial is successful. We are now prepared on the basis of this study, an increase of the number of cases and predict molecular species, and further explore PMTC in recurrent ovarian cancer chemotherapy value.
Recurrent ovarian cancer may reoperation Health, will be right recurrent ovarian cancer surgery and chemotherapy again whether there has been significant controversy. Fourth Militar...
Resistance of ovarian cancer treatment strategy Tumor resistance of the tumor cells to anticancer drugs that showed no reaction of the state of ovarian cancer chemotherapy failure is the ...
Experience with ovarian cancer Treatment of ovarian cancer is still surgery and chemotherapy, although postoperative adjuvant systemic chemotherapy has been the effect cer...
Cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer drug side effects Whitney physicians that cisplatin / paclitaxel chemotherapy in the treatment of ovarian cancer treatment should become the new standard. Ca...
Previous accept carboplatin multidrug chemotherapy in patients with recurrent ovarian cancer Carboplatin and Paclitaxel weekly therapy is safe and effective Kikuchi, the Japanese report, have received platinum multidrug chemotherapy for recurrent ovarian cancer Japanese women, a weekly carboplati...
P53 gene can cure ovarian cancer Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, r...
Ovarian cancer on the related knowledge
Tags: cancer, cases, chemotherapy, cisplatin, clinical, drug, drugs, early, eat, exploration, gene, group, method, ovarian, p53, paclitaxel, patients, pmtc, poor, positive, prognosis, rate, second, study, survival, taxol, therapy, time, treatment, tumor, tumors